Effect of rosiglitazone on cisplatin-induced nephrotoxicity

Renal Failure

Volumn 32, Issue 3, 2010, Pages 368-371

  Ozkaya, Ozan ^a   Yavuz, Oguzhan ^a   Can, Bilge ^a   Dilek, Melda ^a   Savli, Evren ^a   Acikgoz, Yonca ^a   Bedir, Abdlkerim ^a   Akpolat, Tekin ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Experimental; Inflammation; Nephrotoxicity; Rosiglitazone

Indexed keywords

CISPLATIN; CREATININE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; KIDNEY TUBULE DISORDER; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; KIDNEY; KIDNEY TUBULAR NECROSIS, ACUTE; MALE; PPAR GAMMA; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 77950565531     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/08860221003611729     Document Type: Article

References (24)

1. Sugiyama S, Hayakawa M, Kato T, Hanaki Y, Shimizu K, Ozawa T. Adverse effects of anti-tumor drug, cisplatin on rat kidney mitochondria: Disturbances in glutathione peroxidase activity. Biochem Biophys Res Commun. 1989;159:1121-1127. (Pubitemid 19101098)
2. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 1995; 48:761-770.
3. Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of caspases in cisplatin induced injury to renal tubular epithelial cells. Kidney Int. 2001;60:1726-1736. (Pubitemid 32999977)
4. Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin induced acute renal failure in rats. J Lab Clin Med. 1998;131:518-526. (Pubitemid 28278570)
5. Liu H, Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol. 2005;16:1985-1992. (Pubitemid 41716429)
6. Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator activated receptors and inflammation. Pharmacol Ther. 2006;110:371-385.
7. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferatoractivated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341-367.
8. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA. 2003;100:6712-6717. (Pubitemid 36666645)
9. Smeets PJ, Planavila A, van der Vusse GJ, van Bilsen M. Peroxisome proliferator-activated receptors and inflammation: Take it to heart. Acta Physiol (Oxf). 2007;191:171-188. (Pubitemid 47568909)
10. Jiang C, Ting AT, Seed B. PPAR-g agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86. (Pubitemid 28079219)
11. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-g is a negative regulator of macrophage activation. Nature. 1998;391:79-82. (Pubitemid 28079218)
12. Kopple JD, Ding H, Letoha A, et al. L-carnitine ameliorates gentamicin-induced renal injury in rats. Nephrol Dial Transplant. 2002;17:2122-2131. (Pubitemid 35446667)
13. Ramesh G, Reeves WB. TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol. 2003;285:F610-F618. (Pubitemid 37140245)
14. Zahng B, Ramesh G, Norbury CC, Reeves WB. Cisplatininduced nephrotoxicity is mediated by tumor necrosis factor- alpha produced by renal parenchymal cells. Kidney Int. 2007; 72:5-7.
15. Mishima K, Baba A, Matsuo M, et al. Protective effect of cyclic AMP against cisplatin-induced nephrotoxicity. Free Radic Biol Med. 2006;40:1564-1577.
16. Marx N, Mach F, Sauty A, et al. Peroxisome proliferatoractivated receptor-gamma activators inhibit IFN-gammainduced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol. 2000;164: 6503-6508.
17. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator- activated receptor-gamma activators. Circulation. 2000;101:235-238. (Pubitemid 30054148)
18. Eligini S, Banfi C, Brambilla M, et al. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: Evidence for ERK1/2 signaling pathway blockade. Thromb Haemost. 2002;88: 524-532. (Pubitemid 35021614)
19. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell. 2001;104:487-501. (Pubitemid 32201945)
20. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med. 1996;74:13-33. (Pubitemid 26035754)
21. Qian Y, Li S, Ye S, et al. Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats. J Endocrinol Invest. 2008;12:1069-1074.
22. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001;59:1899-1910. (Pubitemid 32336806)
23. Sivarajah A, Chatterjee PK, Patel NS, et al. Agonists of peroxisome proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol. 2003;23:267-276. (Pubitemid 36980722)
24. Lee S, Kim W, Moon SO, et al. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant. 2006;21:2096-2105. (Pubitemid 44295034)